Welcome to our dedicated news page for Sientra (Ticker: SIEN), a resource for investors and traders seeking the latest updates and insights on Sientra.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sientra's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sientra's position in the market.
Rhea-AI Summary
Sientra, Inc. announces successful bidders for assets in breast reconstruction, augmentation, and scar treatment businesses. Tiger Aesthetics Medical, to acquire breast business assets for $42.5 million. Nuance Intermediary, to acquire BIOCORNEUM assets for $8 million. Transactions subject to court approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.12%
Tags
-
Rhea-AI Summary
Sientra, Inc. secures $22.5 million in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process. The company filed for Chapter 11 protection and plans to pursue a sale of its business under Section 363 of the Bankruptcy Code. Sientra aims to emerge with increased financial stability and long-term success under new ownership, with multiple parties showing interest in an acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-65.13%
Tags
-
Rhea-AI Summary
Sientra, Inc. (NASDAQ: SIEN) announced its financial results for Q3 2023, reporting a 13.7% decrease in net sales compared to Q3 2022. The company also highlighted positive improvements in free cash flow usage and adjusted EBITDA loss. Additionally, Sientra presented clinical data for its Viality™ fat transfer system and obtained approval for Viality from Health Canada. The company's CEO expressed enthusiasm for the potential of their portfolio and anticipated an inflection point in 2024 driven by top-line growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.14%
Tags
Rhea-AI Summary
Sientra, Inc. (NASDAQ: SIEN) announced its participation at the Stifel 2023 Healthcare Conference. The company’s management team will participate in a live fireside chat on Wednesday, November 15, 2023, at 8:00 am EST. An on-demand webcast of the presentation will be accessible on the company’s website at www.sientra.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
-
Rhea-AI Summary
Sientra, Inc. announced preliminary unaudited financial results for Q3 2023, with expected revenue in the range of $19.2 million to $19.7 million, compared to $22.6 million in the same period last year. The reduction in revenue was due to softness in the market and seasonal headwinds, resulting in a reduced number of augmentation and reconstruction cases. The company is withdrawing its fiscal year 2023 guidance due to the volatile operating environment. Net cash and cash equivalents as of September 30, 2023, are expected to be in the range of $14.7 to $15.2 million, compared to $26.1 million on December 31, 2022, and $18.6 million on June 30, 2023. Sientra is exploring strategic alternatives to improve its balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.16%
Tags
-
Rhea-AI Summary
Sientra, Inc. (NASDAQ: SIEN) announced its financial results for Q2 2023. The company reported revenue growth of 7.5% and achieved the best operational results in its history with a 95% improvement in operating cash flow and a 63% improvement in adjusted EBITDA. Sientra also obtained FDA clearance for its Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.56%
Tags
Rhea-AI Summary
Sientra, Inc. will release its financial results for Q2 2023 on August 10, 2023, after the market closes. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Domestic callers can dial (844) 735-3763 and international callers can dial (412) 317-5711 to join the call. A live webcast of the conference call will be available on the Investor Relations section of Sientra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
Rhea-AI Summary
Sientra, Inc. has received FDA clearance for its AlloX2 Pro Tissue Expander, making it the first and only MRI-compatible tissue expander available in the US market. The innovation removes 95% of the metal traditionally associated with tissue expander ports and offers faster port filling and drainage, minimal interference with radiation therapy, and enhanced patient comfort. Sientra continues to lead in breast reconstruction with this groundbreaking technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.71%
Tags
Sientra, Inc.
Nasdaq:SIEN
SIEN Rankings
SIEN Stock Data
2.08M
11.05M
9.61%
17.04%
10.94%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States
Santa Barbara
About SIEN
medical devices- plastic surgery: aesthetic and reconstructive, urology